- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02030353
The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors
Feasibility of Using Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors: a Randomized Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Breast cancer is the most commonly diagnosed cancer among African American women in the United States, and in North Carolina (NC), African American women are more likely to die from breast cancer compared to women of other races/ethnicities. Given this disparity and with approximately 90,000 African American breast cancer survivors in NC, it is important to identify modifiable factors that can help improve survival among this population. Behavioral interventions that promote weight management among breast cancer survivors can help reduce risks for prevalent comorbidities, such as cardiovascular disease and diabetes, and potentially improve prognosis and survival. While lifestyle interventions have shown promise in improving body weight in breast cancer survivors, none have focused on weight gain prevention in African American breast cancer survivors, nor evaluated the use of frequent self-weighing as a self-regulation strategy.
Regular self-weighing has been effectively used as an approach for weight maintenance that helps individuals monitor daily weight fluctuations and make small changes in energy balance behaviors. Given that the frequency of self-weighing among breast cancer survivors is unknown, and the importance of self-regulation behaviors for weight maintenance is well established, extending previous work to prevent weight gain among breast cancer survivors is a critical next step for optimizing cancer outcomes. It is unknown whether self-weighing and activity monitoring is a feasible strategy for breast cancer survivors to monitor weight changes and regulate their energy balance. Thus, this three-arm, pilot randomized controlled trial will evaluate two behavioral self-regulation interventions for weight gain prevention (self-regulation or self-regulation plus activity monitoring) compared to a delayed control group among 45 female African-American post-treatment breast cancer survivors. Participants will be randomly assigned to one of three groups: Self-regulation intervention with activity monitoring (n=15); Self-regulation intervention (n=15); and Delayed control (n=15).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female, age 18 or older
- Self-identify as African American or black
- Diagnosed with stage I-IIIA breast cancer within the last 10 years
- Body mass index of 20-45 kg/m²
- Completed cancer treatment (except endocrine treatment) with full recovery of any treatment associated toxicities to ≤ Grade 1 or baseline
- No evidence of progressive disease or second primary cancers
- Have the ability to read, write and speak English
- Have access to the Internet and a computer on at least a weekly basis
- Possession and usage of an Internet e-mail address or willingness to sign up for a free email account
- Willing to be randomized
- Physician approval to participate
Exclusion Criteria:
- History of heart attack or stroke within past 6 months
- Untreated hypertension, hyperlipidemia, or diabetes, unless permission is provided by their health care provider
- Treatment of diabetes with insulin, due to the concerns about hypoglycemia
- Health problems which preclude ability to walk for physical activity (e.g., lower limb amputation)
- Report a diagnosis of psychiatric diseases (schizophrenia, bipolar disorder, depression leading to hospitalization in the past year), drug or alcohol dependency.
- Report a past diagnosis of or treatment for a Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) eating disorder (anorexia nervosa or bulimia nervosa)
- Plans for major surgery (including breast reconstruction) during the intervention time frame
- Have lost and maintained a weight loss of > 10 pounds within the past 6 months or currently participating in another weight loss program
- Currently using prescription weight loss medications
- Currently pregnant, pregnant within the past 6 months, or planning to become pregnant within the next 6 months
- Inability to attend 3 assessment visits (baseline, 3 months, and 6 months) at the University of North Carolina Weight Research Program center
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Self-regulation plus activity monitoring
Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, tailored feedback, and activity monitoring.
|
Individual in-person session, digital smart scale, online intervention, and an activity monitor.
|
|
Experimental: Self-regulation
Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, and tailored feedback.
|
Individual in-person session, digital smart scale, and online intervention.
|
|
No Intervention: Delayed intervention control
Participants will receive an individual in-person session and a digital smart scale, and a modified version of the self-regulation intervention after the 6-month assessment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants with completed assessments at 6 months
Time Frame: 6 months
|
Proportion of participants who complete all 6-month online and in-clinic assessments.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight change
Time Frame: Baseline, 6 months
|
Change in weight, as measured objectively during in-clinic assessments, from baseline to 6 months.
|
Baseline, 6 months
|
|
Change in dietary intake
Time Frame: Baseline, 6 months
|
Change in dietary intake, as measured by the online Automated Self-Administered 24-hour recall, from baseline to 6 months.
|
Baseline, 6 months
|
|
Change in physical activity
Time Frame: Baseline, 6 months
|
Change in physical activity, as measured by the Paffenbarger Exercise Habits Questionnaire, from baseline to 6 months.
|
Baseline, 6 months
|
|
Change in waist circumference
Time Frame: Baseline, 6 months
|
Change in waist circumference, as measured by objective clinic assessment, from baseline to 6 months.
|
Baseline, 6 months
|
|
Change in blood pressure
Time Frame: Baseline, 6 months
|
Change in blood pressure, as measured by objective clinic assessment, from baseline to 6 months.
|
Baseline, 6 months
|
|
Change in cholesterol
Time Frame: Baseline, 6 months
|
Change in cholesterol, as measured by objective clinic assessment, from baseline to 6 months.
|
Baseline, 6 months
|
|
Change in hemoglobin A1c
Time Frame: Baseline, 6 months
|
Change in hemoglobin A1c, as measured by objective clinic assessment, from baseline to 6 months.
|
Baseline, 6 months
|
|
Change in triglycerides
Time Frame: Baseline, 6 months
|
Change in triglycerides as measured by objective clinic assessment, from baseline to 6 months.
|
Baseline, 6 months
|
|
Proportion of participants with completed assessments at 3 months
Time Frame: 3 months
|
Proportion of participants who complete all 3-month online and in-clinic assessments.
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Carmina G. Valle, PhD, MPH, University of North Carolina, Chapel Hill
- Study Director: Deborah F. Tate, PhD, University of North Carolina, Chapel Hill
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCCC1323
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Dana-Farber Cancer InstituteIncyte CorporationActive, not recruitingInflammatory Breast Cancer (IBC)United States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCCompletedBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Xijing HospitalActive, not recruitingBreast Cancer | Breast Cancer (Triple Negative Breast Cancer (TNBC))China
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
BerGenBio ASAMerck Sharp & Dohme LLCTerminatedTriple Negative Breast Cancer | Inflammatory Breast Cancer Stage IVSpain, United States, United Kingdom, Norway
-
CytomX TherapeuticsCompletedNeoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 NegativeUnited States, Spain, Korea, Republic of
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Beaumont HospitalRecruitingRobotic Surgery | Breast Reconstruction | DIEP Flap Breast Reconstruction | Breast Cancer, Breast NeoplasmsIreland
Clinical Trials on Self-regulation plus activity monitoring
-
Wake Forest UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)TerminatedAmnestic Mild Cognitive ImpairmentUnited States
-
Wayne State UniversityCompletedHypertension | HemodialysisUnited States
-
University of PennsylvaniaCompletedObesity | Liver Transplant; Complications | Kidney Transplant; ComplicationsUnited States
-
Texas Tech UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Pennington...RecruitingOverweight Adolescents | Obese AdolescentsUnited States
-
University of South CarolinaUniversity of Colorado, Denver; Brown University; InquisitHealth, Inc.Active, not recruiting
-
Maastricht UniversityCompleted
-
University of ConnecticutNational Heart, Lung, and Blood Institute (NHLBI); Worcester Polytechnic InstituteCompleted
-
University of HoustonAmerican Cancer Society, Inc.; Herald Cancer AssociationCompletedBreast Cancer | Breast NeoplasmsUnited States
-
Columbia UniversityNational Institute on Aging (NIA)Completed